Introduction
============

Diabetes type 2 is a worldwide disease and it is estimated that at the end of 2030 more than 550 million people suffer from this disease ([@B1]). There are several studies showing that vitamin D deficiency may resulted in developing diabetes type 2 ([@B2]--[@B4]). Vitamin D may facilitate insulin function by regulating its receptor expression, so it may be increases insulin sensitivity ([@B5]). Vitamin D may also regulate glucose homeostasis by stimulating insulin release from pancreatic B-cells ([@B6], [@B7]). Therefore, the correction of vitamin D deficiency may result in improved glucose control and has beneficial effects on complications of diabetes type 2 ([@B8]). Lower circulating level of calcidiol was associated with the increased risk of coronary artery disease in diabetic patients ([@B9]). Vitamin D supplementation increases significantly insulin sensitivity in IGT patients ([@B10]). Recently, Malekshah et al. reported high prevalence of vitamin D deficiency in several cities of Iran ([@B11]).

Because of the role of vitamin D in insulin function and the prevalence of vitamin D deficiency in Iran, the aim of this study was to examine the effects of vitamin D supplementation on glucose control and insulin sensitivity and lipid profile in patients with type 2 diabetes.

Methods
=======

The participants of this randomized double-blind placebo-controlled clinical trial study consist of 65 diabetic type 2 patients at the age range of 30--60 years old who agreed to take place in our study between September 2012 and February 2013. An informed consent was obtained from all of the participants. Seven patients discontinued the supplements consumption, three from placebo group and four from vitamin D group. The study completed with 58 patients (36 women and 12 men). Patient selected from Iranian Diabetes Association (IDA). This study was approved by the Tehran University of Medical Sciences (TUMS) ethical committee (ID: 17112) and registered on [www.clinicaltrial.org](www.clinicaltrial.org) as NC 01876563.

The exclusion criteria were consuming vitamin D supplements within 3 months before beginning of the study and having complications of diabetes, thyroid disorders, and using insulin, thiazolidindiones or anti- obesity drugs. None of the women patients were pregnant or breastfeeding. All patients used metformin and/or glibenclamide as anti-diabetic drugs and agreed to maintain their usual dietary and physical activity habits at the time of intervention.

Participants of this study divided into two randomly allocated groups (vitamin D and placebo) by random permuted blocks within the strata (BMI) method. The vitamin D group received 100 microgram or 4000 IU (one tablet of vitamin D) daily and placebo group received one placebo tablet per day for 2 months. Minoo Pharmaceutical, Cosmetic and Hygienic Company made both vitamin D supplements and placebo. Height, hip and waist circumference was measured to the nearest centimeter and weight to the nearest kilogram. BMI was calculated as the weight divided by the square of height. In the beginning of the study and after 2 months, blood samples were taken after 12--14 hours fasting overnight. After centrifuging, serums were separated and stored at −80 C until measuring the concentration of serum calcidiol, lipid profile and insulin. In addition, HbA1c was measured with HPLC columns as long-time control of glucose.

Biochemical measurements: Serum calcidiol was measured using chemiluminecense method with ELECSYS system 2010 with Roche kit (code number: 05894973). Serum insulin was measured by human insulin ELISA kit (Diametra, Italy) with the sensitivity of 0.25 mcIU/ml and an intraassay and interassay of ≤5% and ≤10% respectively. HOMA-IR was calculated using the formula of fasting glucose (mmol/L) × fasting insulin (μIU/mL) / 22.5 ([@B12]).

Statistical analysis: Statistical analysis was performed by using SPSS version 18. All data were shown as mean ± SE. The Kolmogorov smirnoff test was used for determining normality of the parameters and Wilcoxon test and mann-whitnes test were used to analysis of non-normal distribution variables within and between groups. Independent sample *t*-test and paired t-test were used for comparison between groups before and after supplementation and within groups for analysis of normal distribution variables. In all analysis, *P-*value \<0.05 was considered statistically significant.

Results
=======

Vitamin D group consisted of 28 patients (15 men and 13 women) and placebo group consisted of 30 patients (21 men and 9 women) and there was not significant differences in the sex distribution between 2 groups (*P*=0.154). In addition, there was no significant differences in times at sun exposure between two groups (*P*=0.580).

[Table 1](#T1){ref-type="table"} illustrates the baseline characteristics of 2 groups participated in this study. As it demonstrated, there are no significant differences between anthropometric parameters and duration of disease between 2 groups.

###### 

Baseline characteristics of anthropometric parameters in vitamin D and placebo groups before the intervention

  **Variable**               **Vitamin D group (n=28)**   **Placebo group (n=30)**   ***P*-value**
  -------------------------- ---------------------------- -------------------------- ---------------
  Age (yr)                   50.03                        49.90                      0.924
  Weight (kg)                75.73 ± 3.09                 82.32 ± 2.90               0.125
  BMI (kg/m^2^)              27.94 ± 0.92                 28.75 ± 0.95               0.541
  Waist circumference (cm)   92.56 ± 2.33                 96.53 ± 2.23               0.223
  Hip circumference (cm)     104.19 ± 1.88                106.40 ± 1.47              0.356
  WHR                        0.89 ± 0.014                 0.90 ± 0.012               0.348
  Duration (year)            5.89 ±0.84                   6.07±0.73                  0.877

Data are expressed as mean ± SE, t-test was used to detect differences between the groups

[Table 2](#T2){ref-type="table"} illustrates Fasting biochemical characteristics of two groups at baseline and Post intervention. The results show that supplementation with vitamin D caused a significant decrease in HbA1c (*P*\<0.001) and it was still significant after removing the baseline effect (*P*\<0.001, ANCOVA). Serum insulin concentration decreased significantly in vitamin D group (*P*=0.048), it was not significant between two groups at the end of the study but after adjusting for the baseline values the difference got statistically significant (*P*\<0.001, ANCOVA). There was not any significant difference in HOMA-IR between two groups at the end of intervention, but it got statistically significant (*P*=0.036, ANCOVA) after adjusting for the baseline values. HDL-C concentration increased significantly in both vitamin D (*P*=0.046) and placebo receiving groups (*P*=0.028). In addition, mean concentration of FBS and TC increased significantly in placebo group. For TC concentration, the difference between two groups was statistically significant after removing the effect of baseline values (*P*=0.021, ANCOVA). Serum calcidiol was still significantly different between two groups after removing baseline amounts (*P*\<0.001, ANCOVA).

###### 

Fasting biochemical characteristics of vitamin D and placebo groups at baseline and Post intervention

  Treatment group                               Vitamin D group (n=28)   Placebo group (n=30)   *P*.value[^\*^](#TFN3){ref-type="table-fn"}   
  --------------------------------------------- ------------------------ ---------------------- --------------------------------------------- -------
  FBS (mg/dl)                                   baseline                 147.07 ± 10.11         151.23 ± 7.48                                 0.740
  Post-intervention                             147.74 ± 10.16           161.27 ± 7.69          0.288                                         
  difference                                    2.70 ± 9.66              10.03 ± 4.61           0.483                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.782                    0.038                                                                
  TG (mg/dl)                                    baseline                 158.25 ± 12.41         167.43 ± 16.10                                0.656
  Post-intervention                             145.33 ± 10.28           178.20 ± 14.80         0.080                                         
  difference                                    −13.07 ± 13.15           10.76 ± 14.45          0.231                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.329                    0.462                                                                
  TC (mg/dl)                                    baseline                 201.82 ± 7.91          184.53 ± 6.73                                 0.100
  Post-intervention                             189 ± 7.04               200.87 ± 8.70          0.301                                         
  difference                                    −12.88 ± 7.25            16.33 ± 6.93           0.005                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.087                    0.025                                                                
  HDL-C (mg/dl)                                 baseline                 42.29 ± 1.84           41.17 ± 2.15                                  0.697
  Post-intervention                             49.63 ± 3.28             49 ± 3.03              0.888                                         
  difference                                    6.81 ± 3.25              7.83 ± 3.39            0.830                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.046                    0.028                                                                
  LDL-C (mg/dl)                                 baseline                 88.93 ± 7.23           97.37 ± 7.64                                  0.427
  Post-intervention                             88.37 ± 6.94             98.67 ± 7.22           0.311                                         
  difference                                    0.89 ± 7.19              1.30 ± 8.65            0.971                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.903                    0.882                                                                
  HbA1c (%)                                     baseline                 7.29 ± 0.22            7.84 ± 0.28                                   0.132
  Post-intervention                             6.76± 0.18               7.73 ± 0.23            0.002                                         
  difference                                    −0.53 ± 0.08             −0.11 ± 0.08           0.001                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   \<0.001                  0.176                                                                
  Insulin (μIU/mL)                              baseline                 8.24 ± 0.97            7.49 ± 0.58                                   0.505
  Post-intervention                             6.55 ± 0.28              7.96 ± 0.94            0.171                                         
  difference                                    −1.68 ± 0.81             0.47 ± 0.51            0.027                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.048                    0.367                                                                
  MOMA-IR                                       baseline                 2.50 ± 0.19            2.55 ± 0.16                                   0.841
  Post-intervention                             2.38 ± 0.18              2.78 ± 0.19            0.134                                         
  difference                                    −0.14 ± 0.14             0.22 ± 0.13            0.056                                         
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   0.307                    0.092                                                                
  Calcidiol (ng/ml)                             baseline                 15.55 ± 1.91           14.64 ± 2.22                                  0.759
  Post-intervention                             27.50 ± 2.04             15.95 ± 2.20           \<0.001                                       
  difference                                    11.95 ± 1.44             1.92 ± 0.89            \<0.001                                       
  *P*.value[^\#^](#TFN4){ref-type="table-fn"}   \<0.001                  0.040                                                                

Data are expressed as mean ± SE,

Independent samples *t*-test,

Paired *t*-test

Discussion
==========

The results of this study showed that vitamin D supplementation decreased serum insulin concentration and had beneficial effects in decreasing HbA1c in diabetic type 2 patients. There are several studies with similar results supporting this idea that vitamin D is an important nutrient in control of glucose homeostasis ([@B13], [@B14]). Vitamin D intake decreased prevalence of diabetes type 2 in long-time ([@B15]).

One mechanism that plausible for relating vitamin D to diabetes may be its action on insulin receptor in beta cells. Vitamin D can stimulate gene expression of insulin receptor and increases glucose transport from the intestine ([@B5]). Another mechanism is that 1,25 (OH)~2~D3 involves in calcium absorption from the gut and calcium is necessary for insulin release from beta-cells ([@B16], [@B17]). Recently, it has been cleared that beta-cells have receptors for 1,25 (OH)~2~D3, the active form of vitamin D and this cells can convert calcidiol to this form of vitamin ([@B17]).

One study showed that whether calcium is used or not, vitamin D supplementation improves glucose control in adults at high risk of diabetes type 2 ([@B18]).

Supplementation with vitamin D was only related to improved glucose control in diabetic patients with vitamin D deficiency and this nutrient had not any beneficial effect in patients with normal range of serum calcidiol ([@B19]). Supplementation of 1000 IU vitamin D combined with or without calcium in the form of fortified yogurt resulted in decreased HbA1c ([@B20]). However, vitamin D supplementation although can normalize the calcidiol concentration in diabetic patients; it has no long-term effect on glycemic control in this people ([@B21]).

In our study, vitamin D supplementation did not changed serum lipid profile in diabetic patients significantly except for HDL-C. However, the concentration of LDL-C and FBS increased significantly in placebo receiving group. One previous study showed that supplementation with vitamin D did not result in significant reduction in plasma glucose, TC, LDL-C and TG ([@B19]). Moreover, vitamin D supplementation had not significant effect in reducing serum FBS or insulin resistance in one systematic review ([@B22]).

Unlike our results, in the study of Al-Daghri et al. supplementation with vitamin D had decreased significantly serum TC and LDL-C concentration ([@B23]).

One of limitations of our study is the number of patients participated in the study. Maybe, if we used more patients, we could achieve better results such as reduction in some fractions of lipid profile.

Conclusion
==========

Supplementation with UL dose of vitamin D could improve glucose control in diabetic type 2 patients, but did not exhibit any beneficial change in lipid profile except for HDL-C concentration. Therefore, it seems that vitamin D supplementation might be used as a strategy for control of glucose control in these people.
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